These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
400 related articles for article (PubMed ID: 26041287)
41. Selective histonedeacetylase inhibitor M344 intervenes in HIV-1 latency through increasing histone acetylation and activation of NF-kappaB. Ying H; Zhang Y; Zhou X; Qu X; Wang P; Liu S; Lu D; Zhu H PLoS One; 2012; 7(11):e48832. PubMed ID: 23166597 [TBL] [Abstract][Full Text] [Related]
42. Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells. Sun F; Chan E; Wu Z; Yang X; Marquez VE; Yu Q Mol Cancer Ther; 2009 Dec; 8(12):3191-202. PubMed ID: 19934278 [TBL] [Abstract][Full Text] [Related]
43. Promoter-targeted siRNAs induce gene silencing of simian immunodeficiency virus (SIV) infection in vitro. Lim HG; Suzuki K; Cooper DA; Kelleher AD Mol Ther; 2008 Mar; 16(3):565-70. PubMed ID: 18227841 [TBL] [Abstract][Full Text] [Related]
44. HIV-1 latency and virus production from unintegrated genomes following direct infection of resting CD4 T cells. Chan CN; Trinité B; Lee CS; Mahajan S; Anand A; Wodarz D; Sabbaj S; Bansal A; Goepfert PA; Levy DN Retrovirology; 2016 Jan; 13():1. PubMed ID: 26728316 [TBL] [Abstract][Full Text] [Related]
45. Short communication: SAHA (vorinostat) induces CDK9 Thr-186 (T-loop) phosphorylation in resting CD4+ T cells: implications for reactivation of latent HIV. Ramakrishnan R; Liu H; Rice AP AIDS Res Hum Retroviruses; 2015 Jan; 31(1):137-41. PubMed ID: 24528253 [TBL] [Abstract][Full Text] [Related]
46. Inhibitors of the Histone Methyltransferases EZH2/1 Induce a Potent Antiviral State and Suppress Infection by Diverse Viral Pathogens. Arbuckle JH; Gardina PJ; Gordon DN; Hickman HD; Yewdell JW; Pierson TC; Myers TG; Kristie TM mBio; 2017 Aug; 8(4):. PubMed ID: 28811345 [TBL] [Abstract][Full Text] [Related]
47. Histone deacetylase inhibitors induce complex host responses that contribute to differential potencies of these compounds in HIV reactivation. Beliakova-Bethell N; Mukim A; White CH; Deshmukh S; Abewe H; Richman DD; Spina CA J Biol Chem; 2019 Apr; 294(14):5576-5589. PubMed ID: 30745362 [TBL] [Abstract][Full Text] [Related]
48. Histone deacetylase inhibition modulates histone acetylation at gene promoter regions and affects genome-wide gene transcription in Schistosoma mansoni. Anderson L; Gomes MR; daSilva LF; Pereira ADSA; Mourão MM; Romier C; Pierce R; Verjovski-Almeida S PLoS Negl Trop Dis; 2017 Apr; 11(4):e0005539. PubMed ID: 28406899 [TBL] [Abstract][Full Text] [Related]
49. Ex vivo response to histone deacetylase (HDAC) inhibitors of the HIV long terminal repeat (LTR) derived from HIV-infected patients on antiretroviral therapy. Lu HK; Gray LR; Wightman F; Ellenberg P; Khoury G; Cheng WJ; Mota TM; Wesselingh S; Gorry PR; Cameron PU; Churchill MJ; Lewin SR PLoS One; 2014; 9(11):e113341. PubMed ID: 25409334 [TBL] [Abstract][Full Text] [Related]
50. Disruption of polycomb repressor complex-mediated gene silencing reactivates HIV-1 provirus in latently infected cells. Yoon CH; Jang DH; Kim KC; Park SY; Kim HY; Kim SS; Chi SG; Choi BS Intervirology; 2014; 57(2):116-20. PubMed ID: 24642637 [TBL] [Abstract][Full Text] [Related]
51. Crosstalk between histone modifications indicates that inhibition of arginine methyltransferase CARM1 activity reverses HIV latency. Zhang Z; Nikolai BC; Gates LA; Jung SY; Siwak EB; He B; Rice AP; O'Malley BW; Feng Q Nucleic Acids Res; 2017 Sep; 45(16):9348-9360. PubMed ID: 28637181 [TBL] [Abstract][Full Text] [Related]
52. Development of 5' LTR DNA methylation of latent HIV-1 provirus in cell line models and in long-term-infected individuals. Trejbalová K; Kovářová D; Blažková J; Machala L; Jilich D; Weber J; Kučerová D; Vencálek O; Hirsch I; Hejnar J Clin Epigenetics; 2016; 8():19. PubMed ID: 26900410 [TBL] [Abstract][Full Text] [Related]
53. The polycomb group protein enhancer of zeste 2 is a novel therapeutic target for cervical cancer. Ding M; Zhang H; Li Z; Wang C; Chen J; Shi L; Xu D; Gao Y Clin Exp Pharmacol Physiol; 2015 May; 42(5):458-64. PubMed ID: 25739318 [TBL] [Abstract][Full Text] [Related]
54. Histone H3 modifications associated with differentiation and long-term culture of mesenchymal adipose stem cells. Noer A; Lindeman LC; Collas P Stem Cells Dev; 2009 Jun; 18(5):725-36. PubMed ID: 18771397 [TBL] [Abstract][Full Text] [Related]
55. Fuse-binding protein 1 is a target of the EZH2 inhibitor GSK343, in osteosarcoma cells. Xiong X; Zhang J; Liang W; Cao W; Qin S; Dai L; Ye D; Liu Z Int J Oncol; 2016 Aug; 49(2):623-8. PubMed ID: 27278257 [TBL] [Abstract][Full Text] [Related]
56. Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4(+) T cells. Choudhary SK; Archin NM; Margolis DM J Infect Dis; 2008 Apr; 197(8):1162-70. PubMed ID: 18419522 [TBL] [Abstract][Full Text] [Related]
57. Short chain fatty acids potently induce latent HIV-1 in T-cells by activating P-TEFb and multiple histone modifications. Das B; Dobrowolski C; Shahir AM; Feng Z; Yu X; Sha J; Bissada NF; Weinberg A; Karn J; Ye F Virology; 2015 Jan; 474():65-81. PubMed ID: 25463605 [TBL] [Abstract][Full Text] [Related]
58. Pharmacologic reactivation of latent feline immunodeficiency virus ex vivo in peripheral CD4+ T-lymphocytes. McDonnel SJ; Sparger EE; Luciw PA; Murphy BG Virus Res; 2012 Dec; 170(1-2):174-9. PubMed ID: 23073179 [TBL] [Abstract][Full Text] [Related]
59. c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. Jiang G; Espeseth A; Hazuda DJ; Margolis DM J Virol; 2007 Oct; 81(20):10914-23. PubMed ID: 17670825 [TBL] [Abstract][Full Text] [Related]
60. Chromatin maturation of the HIV-1 provirus in primary resting CD4+ T cells. Lindqvist B; Svensson Akusjärvi S; Sönnerborg A; Dimitriou M; Svensson JP PLoS Pathog; 2020 Jan; 16(1):e1008264. PubMed ID: 31999790 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]